
Recent FDA approval of nirsevimab and clesrovimab have transformed RSV prevention in infants, prompting new recommendations from the CDC and AAP and replacing the long-standing role of palivizumab.
Recent FDA approval of nirsevimab and clesrovimab have transformed RSV prevention in infants, prompting new recommendations from the CDC and AAP and replacing the long-standing role of palivizumab.
Published: September 29th 2025 | Updated: